Evidence map›Paper›PMID 38965121›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2024

Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men.

Da Hea Seo, Maripat Corr, Sheena Patel, Li-Yung Lui, Jane A Cauley, Daniel Evans, Theresa Mau, Nancy E Lane

Abstract read
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Da Hea SeoSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Maripat CorrDepartment of Medicine, University of California, San Diego, CA, USA.
Sheena PatelSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Li-Yung LuiSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Jane A CauleyDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Daniel EvansSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Theresa MauSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Nancy E LaneDepartment of Medicine and Rheumatology, University of California, Davis, CA, USA. nelane@ucdavis.edu.ORCID http://orcid.org/0000-0001-7578-8603

Funding

Long term fracture risk and change in peripheral bone in the oldest old men: The MrOS studyR01AG066671 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI BOUXSEIN, MARY L, CAWTHON, PEGGY MANNEN · 2020 to 2024
$13.3M
Skeletal Biology and Biomechanics (SBB) CoreP30AR075055 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 2019 to 2026
$7.1M
The Epidemiology and Genetics of Hip OA in Elderly MenR01AR052000 · NIAMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LANE, NANCY E · 2005 to 2009
$2.5M
NIAMS NIH HHS P30 AR075055NIA NIH HHS R01 AG066671
6 · The paper itself

Abstract

Our study examined associations of the CXC motif chemokine ligand 9 (CXCL9), a pro-inflammatory protein implicated in age-related inflammation, with musculoskeletal function in elderly men. We found in certain outcomes both cross-sectional and longitudinal significant associations of CXCL9 with poorer musculoskeletal function and increased mortality in older men. This requires further investigation. PURPOSE: We aim to determine the relationship of (CXCL9), a pro-inflammatory protein implicated in age-related inflammation, with both cross-sectional and longitudinal musculoskeletal outcomes and mortality in older men.

methodsA random sample from the Osteoporotic Fractures in Men (MrOS) Study cohort (N = 300) was chosen for study subjects that had attended the third and fourth clinic visits, and data was available for major musculoskeletal outcomes (6 m walking speed, chair stands), hip bone mineral density (BMD), major osteoporotic fracture, mortality, and serum inflammatory markers. Serum levels of CXCL9 were measured by ELISA, and the associations with musculoskeletal outcomes were assessed by linear regression and fractures and mortality with Cox proportional hazards models.

resultsThe mean CXCL9 level of study participants (79.1 ± 5.3 years) was 196.9 ± 135.2 pg/ml. There were significant differences for 6 m walking speed, chair stands, physical activity scores, and history of falls in the past year across the quartiles of CXCL9. However, higher CXCL9 was only significantly associated with changes in chair stands (β =  - 1.098, p < 0.001) even after adjustment for multiple covariates. No significant associations were observed between CXCL9 and major osteoporotic fracture or hip BMD changes. The risk of mortality increased with increasing CXCL9 (hazard ratio quartile (Q)4 vs Q1 1.98, 95% confidence interval 1.25-3.14; p for trend < 0.001).

conclusionsGreater serum levels of CXCL9 were significantly associated with a decline in chair stands and increased mortality. Additional studies with a larger sample size are needed to confirm our findings.

Indexed as

BiomarkersBone DensityChemokine CXCL9Muscle StrengthOsteoporotic FracturesAgedAged, 80 and overAgingCross-Sectional StudiesHip JointHumansInflammationLongitudinal StudiesMaleWalking SpeedBiomarkersChemokine CXCL9CXCL9 protein, humanCytokinesFunctional performanceMortalityOsteoporotic fractures

Identifiers

PMID38965121
PMCPMC11427528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.